Skip to content

ANTX

AN2 Therapeutics, Inc.

NASDAQ · Healthcare · Biotechnology · US

$5.89
−1.01%
Ask drillr
1
Insider buys (3m)
3
Insider sells (3m)
-$225.9K
Net value (3m)
+53.9%
Price return (3m)
Form 4 filings
DateInsiderActivitySharesPrice
Sep 2, 2026FitzPatrick Margaret M · directorPurchase2,098$5.53
Aug 19, 2026Readnour Robin Shane · directorSale16,696$6.01
Aug 19, 2026Readnour Robin Shane · directorSale18,706$6.01
Jul 10, 2026Aziz Kabeer · directorA-Award2,852$0.00
Jul 10, 2026Eizen Joshua M · officer: See RemarksSale5,945$4.17
Jul 10, 2026Martin Patricia A. · directorA-Award766$0.00
Jul 10, 2026Marks Gilbert Lynn · directorA-Award2,789$0.00
Jun 2, 2026Williams Sarah Joanne · officer: Principal Accounting OfficerSale265$4.43
Apr 10, 2026Marks Gilbert Lynn · directorA-Award3,775$0.00
Apr 10, 2026Martin Patricia A. · directorA-Award1,192$0.00
Apr 10, 2026Aziz Kabeer · directorA-Award3,775$0.00
Mar 23, 2026Aziz Kabeer · directorA-Award23,742$3.91
Mar 23, 2026Martin Patricia A. · directorA-Award24,999$3.91
Mar 23, 2026Martin Patricia A. · directorA-Award10,362$3.91
Mar 23, 2026Martin Patricia A. · directorA-Award23,742$3.91
Mar 23, 2026FitzPatrick Margaret M · directorA-Award11,463$3.91
Mar 23, 2026FitzPatrick Margaret M · directorA-Award10,362$3.91
Mar 23, 2026FitzPatrick Margaret M · directorA-Award23,742$3.91
Mar 23, 2026Wong Stephanie · directorA-Award24,999$3.91
Mar 23, 2026Wong Stephanie · directorA-Award10,362$3.91
Mar 23, 2026Wong Stephanie · directorA-Award23,742$3.91
Mar 23, 2026Zakrzewski Joseph S · directorA-Award99,999$3.91
Mar 23, 2026Zakrzewski Joseph S · directorA-Award10,362$3.91
Mar 23, 2026Zakrzewski Joseph S · directorA-Award23,742$3.91
Mar 23, 2026Eizen Joshua M · officer: See RemarksA-Award50,150$3.91
Mar 23, 2026Spigelman Melvin K · directorA-Award16,941$3.91
Mar 23, 2026Spigelman Melvin K · directorA-Award10,362$3.91
Mar 23, 2026Spigelman Melvin K · directorA-Award23,742$3.91
Mar 23, 2026Readnour Robin Shane · directorA-Award20,724$3.91
Mar 23, 2026Readnour Robin Shane · directorA-Award23,742$3.91
Institutional positioning

13F filings over the trailing two quarters

New 25Increased 13Reduced 9Sold out 51
FilerActionSharesFiled
VIVO CAPITAL, LLCNew Position3,153,640May 20, 2026
COMMODORE CAPITAL LPNew Position2,333,713May 15, 2026
MILLENNIUM MANAGEMENT LLCIncreased2,222,502May 15, 2026
Spruce Street Capital LPNew Position1,661,073May 14, 2026
ALMITAS CAPITAL LLCUnchanged1,479,129May 15, 2026
VANGUARD CAPITAL MANAGEMENT LLCNew Position1,011,078May 15, 2026
ADAGE CAPITAL PARTNERS GP, L.L.C.New Position1,000,000May 15, 2026
WOODLINE PARTNERS LPIncreased993,671May 15, 2026
CITADEL ADVISORS LLCIncreased951,997Sep 2, 2026
BOXER CAPITAL MANAGEMENT, LLCNew Position749,035May 15, 2026
STONEPINE CAPITAL MANAGEMENT, LLCIncreased713,845May 14, 2026
AMERIPRISE FINANCIAL INCNew Position696,181Jul 17, 2026
SIO CAPITAL MANAGEMENT, LLCNew Position657,200May 14, 2026
ALLY BRIDGE GROUP (NY) LLCNew Position526,315May 18, 2026
PROSIGHT MANAGEMENT, LPNew Position515,754May 15, 2026

Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Sep 2, 2026